Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC). This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback